Unlocking Genetic Mysteries: How Targeted Sequencing Can Help Diagnose Rare Skeletal Conditions
"Discover the role of targeted next-generation sequencing (NGS) in diagnosing short-rib polydactyly syndrome (SRPS) and improving genetic counseling for families at risk."
Short-rib polydactyly syndromes (SRPSs) are a complex group of skeletal dysplasias with an autosomal recessive or digenic recessive inheritance pattern. These conditions are rooted in ciliary dysfunction and are characterized by distinctive features such as shortened ribs, shortened limbs, and polydactyly (the presence of extra digits). Beyond these primary characteristics, SRPS can also involve a range of associated anomalies affecting critical organs like the kidneys, heart, liver, pancreas, and even the genitalia and intestines. Understanding SRPS requires recognizing its diverse manifestations and the underlying genetic causes.
SRPS is further classified into various types, known as short-rib thoracic dysplasias with or without polydactyly, numbered from 1 to 17 (SRTD1~17). Each type is associated with specific gene loci, such as SRTD1 (OMIM 208500) at gene locus 15q13 and SRTD2 (OMIM 611263) at gene locus 3q25.33. These classifications help clinicians and researchers to categorize and study the syndromes more effectively. The genetic complexity means accurate diagnosis often requires advanced molecular techniques.
While previous studies have reported on SRPS cases linked to NEK1 mutations, this article delves into a specific case of SRTD3, which is associated with mutations in the DYNC2H1 gene. By exploring this particular case, we gain insights into the role of targeted next-generation sequencing (NGS) in diagnosing SRTD3 and providing crucial information for genetic counseling.
Why Measurement Matters
Rare skeletal conditions can be difficult to diagnose because their signs may overlap with more common disorders. Targeted sequencing may help clinicians investigate genes associated with a patient's specific clinical features, but its usefulness depends on careful interpretation. Statistics and expected benefits can vary by condition, population, and testing strategy.
Limits of Conventional Diagnosis
Diagnosis commonly draws on clinical examination, family history, imaging, and laboratory evaluation. These approaches can identify characteristic patterns, but they may not reveal the molecular cause of an unusual skeletal presentation. Genetic testing can add information, although results may remain uncertain or require specialist interpretation.
From Observation to Genetics
The study of skeletal disease has progressed from describing physical patterns to investigating their biological causes. Advances in molecular genetics have made it possible to connect some skeletal phenotypes with specific gene changes. This shift has helped establish genetic diagnosis as a complement to clinical assessment rather than a replacement for it.
What is the Role of Targeted NGS in Diagnosing SRPS/SRTD3?
In a recent case, a 29-year-old woman, pregnant for the first time, was referred for genetic counseling at 15 weeks of gestation. Ultrasound scans had revealed several abnormalities in the fetus, including shortened limbs, a narrow chest, and bilateral polydactyly affecting both the hands and feet. These findings collectively pointed towards a diagnosis of SRPS type III. Given these indicators, a chorionic villus sampling was performed to obtain a sample for further genetic analysis.
- CEP120
- DYNC2H1
- DYNC2LI1
- EVC
- EVC2
- FGFR2
- FGFR3
- HOXD10
- IFT122
- IFT140
- IFT172
- IFT52
- IFT80
- KIAA0586
- NEK1
- PAPSS2
- SLC26A2
- SOX9
- TCTEX1D2
- TCTN3
- TTC21B
- WDR19
- WDR34
- WDR35
- WDR60
Expanding Molecular Insight
Current work continues to examine how targeted sequencing can clarify suspected genetic causes of skeletal abnormalities. The approach is most informative when gene selection reflects the patient's clinical presentation and when findings are reviewed alongside imaging and family history. Research remains active because many patients with rare conditions do not receive a definitive molecular diagnosis.
When Testing Falls Short
Targeted sequencing does not guarantee a diagnosis. A test may miss a relevant change if the responsible gene is not included, if the variant lies outside the regions examined, or if available evidence is insufficient for interpretation. Negative or uncertain results therefore need to be understood as limits of the test and current knowledge, not necessarily proof that a genetic cause is absent.
Choosing the Right Test
Targeted sequencing can be more focused than broader sequencing approaches when a particular group of genes is strongly suspected. Broader testing may be considered when the clinical picture is unclear or when targeted testing does not explain the condition. The best choice depends on the suspected disorder, the information already available, and the need to balance scope with interpretive complexity.
Implications for Genetic Counseling
This case underscores the utility of targeted NGS in the diagnosis of fetal skeletal dysplasia and SRPS. The information acquired through this advanced genetic testing is invaluable for genetic counseling, enabling healthcare professionals to provide more accurate risk assessments and inform families about potential outcomes and management strategies.
Integrating the Evidence
Targeted sequencing is most valuable as part of a coordinated diagnostic process. Its results should be interpreted with clinical findings, radiographic patterns, and family history rather than in isolation. This integrated approach can help distinguish a meaningful finding from a result whose significance remains uncertain.
The Next Diagnostic Steps
Future progress may come from improving gene lists, variant interpretation, and the integration of sequencing with detailed clinical data. As knowledge of skeletal biology grows, previously uncertain findings may become easier to interpret. Continued research will also be needed for patients whose conditions are caused by genes or mechanisms not captured by current targeted tests.
Public Systems and Access
The provided sources describe Hawaiʻi state systems rather than genetic diagnosis: the Hawaiʻi Tourism Authority reports on tourism's contribution to the state's 2025 economy, while Hawaii.gov provides resources for government, residents, businesses, and visitors. The myHawaii service uses single sign-on across multiple applications, and the Department of Taxation addresses tax violations across Hawaiʻi's economy. These sources do not provide evidence about access to targeted sequencing, rare skeletal conditions, or related healthcare disparities, so broader conclusions about those issues cannot be drawn from them.
Patients Behind the Diagnosis
For people living with an undiagnosed skeletal condition, uncertainty can affect medical decisions, family planning, and access to appropriate support. A molecular result may provide useful clarity, but it can also raise questions when findings are uncertain or do not fully explain a patient's symptoms. Genetic counseling and continued clinical follow-up remain important parts of interpreting what testing means for an individual and their family.